Red X iconGreen tick iconYellow tick icon

Monday 29 June 2015 2:59pm

Dr Chris Jackson, oncologist, and CTCR researcher and Advisory Board member, was interviewed about the impact of a new immunotherapy drug for advanced melanoma patients.

The 3D news programme on TV3, interviewed Chris, and two patients undergoing treatment (link to the item no longer available).

The drug, available only as part of a clinical trial, works by aiding the immune system to recognise and attack the tumour. Often cancers can evade the immune system's defences. The results for some patients appear to be very significant and indicate hope for immunotherapy's potential for a range of cancers.

More about CTCR's work in immunotherapy

Back to top